ARS Pharmaceuticals (SPRY) EBIAT: 2022-2025
Historic EBIAT for ARS Pharmaceuticals (SPRY) over the last 4 years, with Sep 2025 value amounting to -$51.2 million.
- ARS Pharmaceuticals' EBIAT fell 167.41% to -$51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$80.0 million, marking a year-over-year decrease of 63.00%. This contributed to the annual value of $8.0 million for FY2024, which is 114.71% up from last year.
- According to the latest figures from Q3 2025, ARS Pharmaceuticals' EBIAT is -$51.2 million, which was down 13.97% from -$44.9 million recorded in Q2 2025.
- Over the past 5 years, ARS Pharmaceuticals' EBIAT peaked at $49.9 million during Q4 2024, and registered a low of -$51.2 million during Q3 2025.
- Its 3-year average for EBIAT is -$16.0 million, with a median of -$15.0 million in 2023.
- As far as peak fluctuations go, ARS Pharmaceuticals' EBIAT soared by 796.62% in 2024, and later tumbled by 258.60% in 2025.
- Over the past 4 years, ARS Pharmaceuticals' EBIAT (Quarterly) stood at -$14.4 million in 2022, then skyrocketed by 50.32% to -$7.2 million in 2023, then surged by 796.62% to $49.9 million in 2024, then plummeted by 167.41% to -$51.2 million in 2025.
- Its last three reported values are -$51.2 million in Q3 2025, -$44.9 million for Q2 2025, and -$33.9 million during Q1 2025.